Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of S-812217 added to antidepressants in major depressive disorder
jRCT2031220423Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zuranolone in major depressive disorder (MDD) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: HAM-D17 response at Day 15 (Part A). Started Nov 2022; status: completed.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2031220423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220423.